| 摘要: |
| 替格瑞洛是一种新型口服抗血小板药物，通过直接作用于二磷酸腺苷（ADP）受体P2Y12抑制ADP介导的血小板聚集，发挥抗血小板功能。除抑制血小板聚集外，替格瑞洛还表现出生物多效性，如增加冠状动脉血流、限制心肌梗死面积和诱发呼吸困难等。研究认为替格瑞洛的生物多效性与腺苷密切相关，但目前有关替格瑞洛对血浆腺苷浓度影响的研究结果并不一致，可能与血浆腺苷浓度的不同测定方法（尤其是终止液配比）、不同测定时间点等有关。规范血浆腺苷浓度的测定方法以及动态监测服用替格瑞洛后血浆腺苷浓度的变化，有助于进一步明确替格瑞洛对血浆腺苷浓度的影响。 |
| 关键词: 冠心病 替格瑞洛 腺苷 血浆浓度 |
| DOI：10.16781/j.0258-879x.2019.06.0664 |
| 投稿时间：2019-05-13修订日期：2019-06-03 |
| 基金项目: |
|
| Effect of ticagrelor on plasma adenosine concentration in patients with coronary heart disease |
| XU Ru-ming,MA Li-ping* |
(Department of Cardiovasology, Changhai Hospital, Naval Medical University(Second Military Medical University), Shanghai 200433, China
*Corresponding author) |
| Abstract: |
| Ticagrelor is a novel oral antiplatelet agent. It can inhibit platelet aggregation mediated by adenosine diphosphate (ADP) by directly acting on ADP receptor P2Y12, exerting its antiplatelet function. In addition, ticagrelor showed bioavailability like increasing coronary blood flow, reducing myocardial infarction size and inducing dyspnea. These effects were thought to be closely related to adenosine. However, recent publications about the effect of ticagrelor on plasma adenosine concentration were inconsistent, which may be caused by different determination methods, especially various compositions of stop solution, and different sampling time points. Standardized determination method of plasma adenosine concentration and dynamically monitoring the changes of plasma adenosine after taking ticagrelor may help to further illustrate the influence of ticagrelor on plasma adenosine concentration. |
| Key words: coronary disease ticagrelor adenosine plasma concentration |
